Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus reuteri TISTR 2736
- Development stage
- Preclinical
- Lead developer
- Thailand Institute of Scientific and Technological Research
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri TISTR 2736 is a specific probiotic bacterial strain investigated for its potential therapeutic effects in metabolic disorders, particularly type 2 diabetes. In preclinical models, it has been shown to improve glucose homeostasis and carbohydrate metabolism. Its mechanism of action involves the activation of the hepatic IRS1/PI3K/AKT signaling pathway, which is crucial for insulin sensitivity. Additionally, the strain helps mitigate oxidative stress and reduces levels of inflammatory mediators, thereby addressing systemic insulin resistance and metabolic dysfunction.
- Other names
- L. reuteri TISTR 2736
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)IRS1 (Insulin receptor substrate 1)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on Lactobacillus reuteri TISTR 2736.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus reuteri TISTR 2736.